When a patient with epilepsy develops atrial fibrillation or a venous thrombosis, the anticoagulant is often chosen by a cardiologist or physician who may not look closely at the antiseizure regimen.
Carbamazepine, phenytoin, phenobarbital and primidone induce CYP3A4 and P-glycoprotein and can lower DOAC levels enough to matter. Ask what the patient takes before the first dose. If a strong inducer is involved, talk to the neurologist about switching to a non-inducing drug, or reconsider the anticoagulant.
The interaction works in reverse too: stopping an inducer raises DOAC levels over the following weeks.
- Ask for the full antiseizure regimen before prescribing a DOAC
- Flag carbamazepine, phenytoin, phenobarbital and primidone as strong inducers
- Coordinate any switch with the treating neurologist
- Remember that stopping an inducer raises DOAC exposure
Why it matters
An unnoticed enzyme inducer can quietly leave an anticoagulated patient unprotected.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free